Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 51

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 51
---
 countries where labor unrest is more common than in the Netherlands;

    ●
    difficulties associated with staffing and managing international operations, including differing labor relations; and

    ●
    business interruptions resulting from geo-political actions, including war and terrorism, pandemics, or natural disasters, including earthquakes, typhoons, floods and fires.

If
we are sued for product or professional liability, we could face substantial liabilities that exceed our resources.

Renovaro
Cube’s business depends upon its ability to obtain reliable and accurate test results that incorporate rapidly evolving understanding
of how to interpret minute signals detected by Renovaro Cube’s assays as indications of potential presence of disease. Actual or
perceived errors resulting from laboratory or reporting errors, false positive or false negative test results, or the manufacture, design,
or labelling of Renovaro Cube’s products, could subject Renovaro Cube to product liability or professional liability claims. A product
liability or professional liability claim against Renovaro Cube could result in substantial damage and be costly and time-consuming to
defend. Any liability claim brought against Renovaro Cube, with or without merit, could increase its insurance rates or prevent it from
securing insurance coverage in the future. Additionally, any liability lawsuit could damage Renovaro Cube’s reputation or force
it to delay or suspend sales of its products. The occurrence of any of these events could have a material adverse effect on Renovaro Cube’s
business, results of operations, financial condition and prospects. The same would apply to products of BioSymetrics.

Risks Related to our Common Stock

Our stock price has been and will likely continue to be volatile
and may decline regardless of our operating performance.

Our stock price has fluctuated in the past and can be expected to be volatile
in the future. From September 26, 2024, through September 26, 2025, the reported sale price of our Common Stock has fluctuated between
$1.91 and $0.13 per share. The stock market in general and the market for biotechnology and technology companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may experience losses on their investment in our Common Stock. The market price of our Common Stock may be influenced by many
factors, including the following:

    ●
    negative publicity;

    ●
    our compliance with Nasdaq rules and regulations;